Exozymes (EXOZ) Invested Capital (2025 - 2026)

Exozymes (EXOZ) posted quarterly Invested Capital of $108682.0 for Q4 2025, down 8.85% quarter-over-quarter from $119236.0 in Q3 2025.

Exozymes (EXOZ) Invested Capital (2025 - 2026) Analysis & Trends

Exozymes (EXOZ) has reported Invested Capital for 1 consecutive years, with $108682.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Invested Capital changed N/A year-over-year to $108682.0; the TTM figure through Dec 2025 stood at $357511.0 (changed N/A YoY), while the FY2025 annual figure was $108682.0, changed N/A from the prior year.
Invested Capital retreated to $108682.0 in Q4 2025 per EXOZ's latest filing, from $119236.0 in the prior quarter.
Across five years, Invested Capital topped out at $129593.0 in Q2 2025 and bottomed at $108682.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	190.90 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.45 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	380.00 Mn
10	Exozymes	62.35 Mn	62.35 Mn	-	86,970.00

Download Data